Last updated: 2026-09-16 17:54:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Altimmune, Inc. (ALT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3,25, with a market capitalisation of $641,91M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2,56 to $6,44. This page covers its latest market performance, valuation, price trends and company information.
$641,91M | |
$3,27 | |
$44.550,00 | |
$1,51 | |
$3,23 | |
1,54M | |
4,46M | |
-- | |
$6,44 | |
$2,56 | |
-- | |
-- |
Altimmune, Inc. (ALT) is currently trading at $3,25 as of 2026-09-16 17:38:13, up 0,46% ($0,02) from the previous close of $3,23
During today's regular trading session, ALT has traded between $1,51 and $44.550,00, with a trading volume of 1,54M shares. The current price is near the lower end of today's range.
Over the past seven days, Altimmune, Inc. (ALT) moved from $3,42 to $3,25, representing a decline of 5,12% ($0,17).
The stock traded between $3,21 and $3,55 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 3,09 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 17,7%
ALT is currently trading at $3,25, placing it 17,7% of the way from its 52-week low of $2,56 to its 52-week high of $6,44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 57 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Altimmune, Inc. (ALT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.